Iclusig incyte?

What is Iclusig, and who manufactures it?

Iclusig is a medication used to treat certain types of leukemia and other blood cancers [1]. It is a kinase inhibitor, which means it works by blocking specific enzymes in the body that contribute to cancer cell growth [2]. Iclusig is manufactured by Incyte Corporation, a biopharmaceutical company based in Wilmington, Delaware [1].

How does Iclusig work?

Iclusig works by inhibiting the activity of various kinases, including BCR-ABL, which is a protein associated with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [3]. By blocking this protein, Iclusig helps to slow or stop the growth and proliferation of cancer cells [4].

What are the benefits and risks of Iclusig?

Iclusig has been shown to improve symptoms and increase survival rates in patients with CML and Ph+ ALL [5]. However, it can also cause side effects, such as diarrhea, rash, and fatigue [1]. In rare cases, Iclusig may cause more serious side effects, including blood clots and heart problems [6].

Who is eligible to take Iclusig?

Iclusig is approved for use in adults with CML and Ph+ ALL who have received prior therapy [1]. It is not recommended for patients with a history of serious cardiac disease or those who are taking certain medications that may interact with Iclusig [7].

When will the patent for Iclusig expire?

According to DrugPatentWatch.com, the patent for Iclusig is set to expire in 2028 [8].

References:

[1] Incyte Corporation. (2020). Iclusig (ponatinib) Tablets.

[2] National Cancer Institute. (2020). Kinase Inhibitors.

[3] Cancer Research UK. (2020). Chronic myeloid leukaemia (CML).

[4] American Cancer Society. (2020). Chronic Myeloid Leukemia (CML).

[5] Incyte Corporation. (2020). Iclusig Clinical Data.

[6] FDA. (2020). Iclusig (ponatinib) tablets.

[7] Medscape. (2020). Iclusig (ponatinib): Uses, Side Effects, Dosage.

[8] DrugPatentWatch.com. (2022). Iclusig (ponatinib) Patent Expiration.